1
Clinical Trials associated with COVID-19 Specific T Cell derived exosomes(Tc Erciyes University) / Unknown statusPhase 1IIT Aerosol Inhalation of the Exosomes Derived From Allogenic COVID-19 T Cell in the Treatment of Early Stage Novel Coronavirus Pneumonia
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused mass mortality in the last 3 months that necessitates urgent development of new therapeutical agents. So far there is no effective anti-viral drug to reduce viral load that has critical importance to prevent progress into severe viral pneumonia and systemic hyper inflammation state. This project is to offer a biologic agent based on T cell derived exosomes. This is a novel approach using our proprietary protocols for drug development. This clinical trial is to test the safety and efficacy of this new agent following targeted delivery by metered dose inhaler. The project have received proper approvals from the Turkish Ministry of Health and Erciyes University, Kayseri Turkey. Turk-Patent Application Number: PCT/TR2020/050302
100 Clinical Results associated with COVID-19 Specific T Cell derived exosomes(Tc Erciyes University)
100 Translational Medicine associated with COVID-19 Specific T Cell derived exosomes(Tc Erciyes University)
100 Patents (Medical) associated with COVID-19 Specific T Cell derived exosomes(Tc Erciyes University)
100 Deals associated with COVID-19 Specific T Cell derived exosomes(Tc Erciyes University)